An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Envafolimab (Primary) ; Lenvatinib (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- Sponsors 3D Medicines
- 04 Jun 2024 Results ( As of July 12, 2023, n=32) assessing effects of Envafolimab in combination with Lenvatinib for Chinese patients with advanced EC presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 05 May 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Aug 2024.
- 20 Jun 2022 Status changed from not yet recruiting to recruiting.